迈威生物-U
(688062)
| 流通市值：62.54亿 | | | 总市值：122.40亿 |
| 流通股本：2.04亿 | | | 总股本：4.00亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 44,788,452.49 | 199,781,622.22 | 141,095,928.06 | 115,528,061.72 |
| 营业收入 | 44,788,452.49 | 199,781,622.22 | 141,095,928.06 | 115,528,061.72 |
| 二、营业总成本 | 336,094,745.3 | 1,259,798,298.88 | 844,467,620.3 | 566,927,225.5 |
| 营业成本 | 9,975,563.63 | 28,951,667.25 | 10,638,096.49 | 6,172,130.32 |
| 税金及附加 | 1,676,304.11 | 6,051,939.54 | 2,711,149.64 | 1,483,222.73 |
| 销售费用 | 44,745,912.76 | 191,672,154.93 | 168,466,717.93 | 113,176,214.49 |
| 管理费用 | 53,864,887.53 | 213,527,605.44 | 158,902,611.01 | 111,641,931.09 |
| 研发费用 | 208,545,133.67 | 782,869,340.28 | 481,008,266.28 | 322,124,870.91 |
| 财务费用 | 17,286,943.6 | 36,725,591.44 | 22,740,778.95 | 12,328,855.96 |
| 其中:利息费用 | 18,773,815.68 | 57,780,247.68 | 39,149,300.51 | 25,738,580.87 |
| 其中:利息收入 | 1,728,644.68 | 20,916,960.72 | 17,100,314.54 | 13,346,962.57 |
| 加:公允价值变动收益 | 18,138.89 | 493,457.59 | 210,231.23 | 179,946.72 |
| 加:投资收益 | -1,459,211.51 | -4,218,903.47 | -2,716,376.47 | -1,737,207.91 |
| 资产减值损失(新) | -2,718,297.03 | -5,526,750.78 | -8,415,959.33 | -7,355,098.67 |
| 信用减值损失(新) | -498,752.85 | -2,224,140.72 | 2,122,854.37 | 2,061,693.37 |
| 其他收益 | 4,943,462.68 | 28,013,323.4 | 20,136,241.28 | 14,945,103.26 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -291,020,952.63 | -1,043,479,690.64 | -692,034,701.16 | -443,304,727.01 |
| 加:营业外收入 | 186.19 | 32,960.54 | 32,840.54 | 12,040.54 |
| 减:营业外支出 | 1,382,699.93 | 4,024,748.66 | 2,109,217.92 | 1,048,252.89 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -292,403,466.37 | -1,047,471,478.76 | -694,111,078.54 | -444,340,939.36 |
| 减:所得税费用 | 54,174 | -906,773.28 | 1,904,086.4 | 1,904,086.4 |
| 六、净利润 | -292,457,640.37 | -1,046,564,705.48 | -696,015,164.94 | -446,245,025.76 |
| 持续经营净利润 | -292,457,640.37 | -1,046,564,705.48 | -696,015,164.94 | -446,245,025.76 |
| 归属于母公司股东的净利润 | -291,728,135.28 | -1,043,919,217.28 | -694,090,343.42 | -444,982,242.13 |
| 少数股东损益 | -729,505.09 | -2,645,488.2 | -1,924,821.52 | -1,262,783.63 |
| (一)基本每股收益 | -0.73 | -2.61 | -1.74 | -1.11 |
| (二)稀释每股收益 | -0.73 | -2.61 | -1.74 | -1.11 |
| 八、其他综合收益 | -41,128.07 | 278,847.66 | -1,015,688.86 | 568,007.37 |
| 归属于母公司股东的其他综合收益 | -41,128.07 | 278,847.66 | -1,015,688.86 | 568,007.37 |
| 九、综合收益总额 | -292,498,768.44 | -1,046,285,857.82 | -697,030,853.8 | -445,677,018.39 |
| 归属于母公司股东的综合收益总额 | -291,769,263.35 | -1,043,640,369.62 | -695,106,032.28 | -444,414,234.76 |
| 归属于少数股东的综合收益总额 | -729,505.09 | -2,645,488.2 | -1,924,821.52 | -1,262,783.63 |
| 公告日期 | 2025-04-29 | 2025-03-31 | 2024-10-31 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |